Allianz Asset Management
KYNB

Allianz Asset Management’s Kyntra Bio KYNB Stock Holding History

Allianz Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,014
Closed -$940K – 2208
2020
Q4 		$940K Buy
+1,014
New +$1.07M ﹤0.01% 1496
2020
Q1 		– Sell
-1,058
Closed -$1.13M – 2563
2019
Q4 		$1.13M Sell
1,058
-1,714
-62% -$1.75M ﹤0.01% 2130
2019
Q3 		$2.58M Sell
2,772
-2
-0.1% -$2.2K ﹤0.01% 1722
2019
Q2 		$3.13M Buy
2,774
+808
+41% +$884K ﹤0.01% 1705
2019
Q1 		$2.67M Buy
1,966
+1,004
+104% +$1.36M ﹤0.01% 1734
2018
Q4 		$1.11M Buy
962
+506
+111% +$569K ﹤0.01% 1989
2018
Q3 		$692K Buy
456
+102
+29% +$157K ﹤0.01% 2322
2018
Q2 		$554K Sell
354
-106
-23% -$138K ﹤0.01% 2366
2018
Q1 		$532K Buy
460
+58
+14% +$76.4K ﹤0.01% 2365
2017
Q4 		$476K Sell
402
-60
-13% -$75.2K ﹤0.01% 2428
2017
Q3 		$621K Buy
+462
New +$487K ﹤0.01% 2362

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Allianz Asset Management's KYNB Position: Q1 2021 in Review

Allianz Asset Management sold out of Kyntra Bio (KYNB) in Q1 2021, closing a stake of 1,014 shares — an estimated $940K sold.

Allianz Asset Management first reported a position in KYNB in Q3 2017 and held it in 11 quarters. The position peaked at $3.13M in Q2 2019. 198 funds tracked by Wall St. Rank hold KYNB as of Q1 2021.

  • Allianz Asset Management reported no remaining Kyntra Bio position as of Q1 2021 after selling out during the quarter.
  • Allianz Asset Management sold 1,014 Kyntra Bio shares in Q1 2021, an estimated $940K.
  • Allianz Asset Management first reported a position in Kyntra Bio in Q3 2017 and held it in 11 quarters.
  • Allianz Asset Management's Kyntra Bio position peaked at $3.13M in Q2 2019.
  • 198 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2021.

Based on Allianz Asset Management's 13F filing for Q1 2021, filed 13 May 2021.